Weekly ASEAN Regulatory Digest
Hi,
Welcome to the first edition of the Weekly ASEAN Regulatory Digest by The Regulatory Compass.
I hope you will find in this edition and future ones the resources you need to maintain a smooth and effective regulatory watch.
The TRC team and I remain at your disposal.
This week
Singapore
HSA officially accepts eCTD submissions for therapeutic product dossiers
Singapore’s Health Sciences Authority now accepts regulatory submissions in eCTD format through its portal, using SG-HSA eCTD version 1.1. The change is part of a broader push toward more standardized and digitally managed filing processes for therapeutic products. While non-eCTD submissions are still temporarily accepted, the direction of travel is clearly toward electronic submission as the preferred model.
Implication:
This matters because Singapore often acts as a reference market in ASEAN. Companies that submit dossiers in multiple markets should now expect greater pressure to align their internal publishing, document control, and submission planning with eCTD requirements. In practice, this may mean upgrading regulatory operations, training teams on eCTD lifecycle management, and ensuring consistency across global and regional dossiers.
China
Revised Drug Administration Law implementing regulations take effect.
China’s updated implementing regulations introduce a more structured framework for drug innovation, supervision, and compliance. They are intended to support faster development pathways and a more predictable environment for innovative products, while also strengthening oversight of clinical development, distribution, and online medicine sales.
Implication:
For companies active in China, this is a meaningful regulatory shift rather than a routine update. The reforms suggest that innovative products may gain a clearer path to market, but the trade-off is tighter enforcement and more detailed compliance expectations. Firms should review how these rules affect trial planning, MA strategy, anti-diversion controls, and e-commerce channels, especially if they distribute prescription products through digital platforms.
New protections for data and selected product categories.
The revised framework includes data protection for drugs containing new chemical substances, as well as market exclusivity for certain pediatric and rare-disease medicines. This is designed to encourage R&D investment and improve incentives for products that address unmet medical needs.
Implication:
This may improve the business case for filing innovative or specialty medicines in China, particularly where exclusivity could materially affect launch timing and commercial planning. It also means regulatory and commercial teams should work more closely together on lifecycle strategy, because the value of protection windows may influence where and when products are introduced in the region.
South Korea
MFDS hosted APFRAS 2026 in Seoul
Korea’s Ministry of Food and Drug Safety hosted the Asia-Pacific food regulatory forum, which focused on regional cooperation and harmonization. Although the event is broader than pharmaceuticals alone, it is still relevant because it reflects the wider regulatory direction in Asia-Pacific: greater alignment, more collaboration, and a stronger focus on shared standards.
MFDS reported progress from APFRAS 2026
MFDS said the forum ended with tangible progress toward regulatory harmonization, reinforcing its role as a leading regional regulator that actively participates in cross-border coordination efforts.
Implication:
For life sciences companies, this suggests that Korea will continue to be part of the broader APAC convergence conversation. Even when the immediate topic is food regulation, the institutional pattern matters: regulators are increasingly willing to coordinate on common principles, which can eventually influence expectations in pharmaceuticals, devices, and safety oversight.
MFDS medical device rule amendments remain highly relevant
MFDS’s medical device update adds stronger cybersecurity documentation requirements and broadens the kinds of clinical evidence that can support submissions. The changes matter most for connected devices, software-driven products, and manufacturers relying on foreign clinical data or nontraditional evidence packages.
Implication:
Device companies targeting Korea should review technical documentation now rather than later. Cybersecurity is no longer a peripheral issue, and clinical evidence planning needs to be more deliberate, especially if the product includes software, connectivity, or AI-enabled functions. This also signals that Korea is expecting more mature technical dossiers, so companies with weaker evidence packages may face longer review cycles or requests for additional data.